NeoGenomics Signs Working with Cancer Pledge in Support of Employees
2024年2月1日 - 9:05PM
ビジネスワイヤ(英語)
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing
services company, today announced that the Company has signed the
Working with Cancer Pledge. By taking the pledge, NeoGenomics
demonstrates its commitment to supporting team members living with
or caring for a loved one with cancer. Additionally, the company
aims to open the conversation around cancer in the workplace and
ensure our employees are aware of the resources available to
them.
“Studies suggest that 1 in 2 men and 1 in 3 women1 will be
diagnosed with cancer in their lifetime, which means there is a
strong possibility that some of our teammates will be impacted by
cancer while working with us,” said Gary Passman, Chief Culture
Officer at NeoGenomics. “As a leading oncology testing services
company, it is our privilege to sign the Working with Cancer
Pledge, which reinforces our ongoing efforts to create an inclusive
workplace that provides our employees and their families with the
resources they need in the fight against cancer.”
NeoGenomics supports its employees working with cancer by
providing job security during treatment, access to our medical team
offering support and education to understand their diagnosis,
clinical trial matching, and testing covered by our insurance
provider, among other things.
About Working with Cancer
Working with Cancer aims to completely erase the stigma and
insecurity of cancer at work. Today, the program initially launched
by Publicis Groupe is an alliance of major international companies,
with over 600 pledging businesses impacting up to 20 million
employees, united by the aim to create an open, supportive, and
recovery-forward culture for employees with cancer.
About NeoGenomics, Inc.
NeoGenomics, Inc. specializes in cancer genetics testing and
information services, providing one of the most comprehensive
oncology-focused testing menus for physicians to help them diagnose
and treat cancer. The Company’s Advanced Diagnostic Division also
serves pharmaceutical clients in clinical trials and drug
development.
Headquartered in Fort Myers, FL, NeoGenomics operates CAP
accredited and CLIA certified laboratories for full-service sample
processing in Fort Myers, Florida; Aliso Viejo and San Diego,
California; Research Triangle Park, North Carolina; and Houston,
Texas; and a CAP accredited full-service, sample-processing
laboratory in Cambridge, United Kingdom. NeoGenomics also has
several, small, non-processing laboratory locations across the
United States for providing analysis services. NeoGenomics serves
the needs of pathologists, oncologists, academic centers, hospital
systems, pharmaceutical firms, integrated service delivery
networks, and managed care organizations throughout the United
States, and pharmaceutical firms in Europe and Asia.
Reference:
- National Cancer Institute,
https://www.cancer.gov/about-cancer/understanding/statistics
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240201911708/en/
For further information, please contact: NeoGenomics,
Inc. Investors: Kendra Sweeney kendra.sweeney@neogenomics.com
Media: Andrea Sampson Sampson Public Relations Group
asampson@sampsonprgroup.com
NeoGenomics (NASDAQ:NEO)
過去 株価チャート
から 4 2024 まで 5 2024
NeoGenomics (NASDAQ:NEO)
過去 株価チャート
から 5 2023 まで 5 2024